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Sustained HBs seroconversion during lamivudine and adefovir dipivoxil combination therapy for lamivudine failure (3) (4) (5) . ADV has a proven clinical benefit in the treatment of lamivudine resistance with a significant inhibition of viral replication and improvement in liver function after 1 year of therapy. Despite the fact that ADV and lamivudine are not cross-resistant (6, 7) , it is still debated whether the best treatment regimen for lamivudine resistance should rely on the switch to adefovir dipivoxil or on the addition of this drug to ongoing lamivudine (3) (4) (5) .
In the Lyon Liver Department, we followed a cohort of 60 patients that received adefovir dipivoxil in a compassionate use program from the AFSSAPS (French Drug Agency) for lamivudine resistance. All patients received ADV in addition to lamivudine. The patients were prospectively followed up for a mean period of 10.3 months (range 3 months to 21 months).
One of these patients lost serum HBsAg ( Figure 1 ). This 41-year-old man with chronic hepatitis B failed entecavir therapy in a clinical trial, then received lamivudine and became resistant to lamivudine. He was treated succesfully with ADV in addition to lamivudine.
Lamivudine resistance was associated with the selection of a L180M+M204V polymerase mutant. After the addition of ADV, serum HBV DNA levels droped by more than 4 Log 10 which was followed by HBsAg clearance after 22 months of combination therapy. This occurred simultaneously with HBeAg clearance and was not accompanied by an hepatitis flare. Moreover, anti-HBs antibody titers rose to 1000 mIU/mL after 32 months of the new treatment regimen. In parallel, HBV DNA declined below 100 copies / mL by a quantitative real time PCR assay. Analysis of intrahepatic viral DNA showed a significant decline of total HBV DNA and cccDNA (figure 1) which was accompanied by a decrease of the number of infected cells expressing viral antigens below the detection limit of immunostaining (data not shown). Evolution of serum HBsAg levels was parallel to that of HBV DNA in serum and liver.
In parallel, liver histology analysis showed an improvement in both the activity index and fibrosis score. No virological or biochemical relapse was observed until the last visit three months after cessation of therapy.
It is very unlikely that this favorable outcome is due to spontaneous HBs seroconversion. However, we cannot exclude killing by T cells of a minor proportion of the liver since ALT levels were slightly elevated but close to the ULN before HBsAg elimination. Furthermore, HBeAg clearance was simultaneous to that of HBsAg, and did not precede it. Interestingly, the longitudinal analysis of viral genome sequence, confirmed that lamivudine resistance was due to a known mutation in the viral polymerase, and neither a selection of basic core promoter or pre-core stop codon mutation nor a selection of an adefovir resistant mutant was observed throughout the evolution. Analysis of intrahepatic viral DNA showed a sharp decline of total intrahepatic viral DNA consistent with the inhibition of viral DNA synthesis.
Furthermore, a significant decline of viral cccDNA by 2 log10 copies/cell was observed in agreement with the results of another study in patients receiving adefovir dipivoxil (8) . It was associated with a significant decline of HBV antigen -expressing cells below the detection limit of immunostaining assays. Therefore, one may hypothesize that the decline of intrahepatic viral load may have been associated with the sudden restoration of non cytolytic TH1 response followed by HBs seroconversion (9) .
Furthermore, the combination of the virological and biochemical response was associated with an improvement of liver histology including a significant regression of liver fibrosis score.
In conclusion, we have reported the case of a patient with chronic hepatitis B failing lamivudine therapy who received a combination of adefovir dipivoxil and lamivudine and showed a dramatic drop in viral load both in the serum and the liver that was accompanied by HBsAg seroconversion and significant improvement in liver histology. In patients who previously failed lamivudine therapy, proactive antiviral treatment may lead to a beneficial virological and clinical effect. 
